197 related articles for article (PubMed ID: 8792694)
1. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM
Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
[TBL] [Abstract][Full Text] [Related]
3. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
4. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
[TBL] [Abstract][Full Text] [Related]
5. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
[TBL] [Abstract][Full Text] [Related]
6. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
Endo M; Sugihara K
Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817
[TBL] [Abstract][Full Text] [Related]
7. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W
Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Chiba N
Can J Gastroenterol; 1997 Sep; 11 Suppl B():66B-73B. PubMed ID: 9347181
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
[TBL] [Abstract][Full Text] [Related]
12. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
[TBL] [Abstract][Full Text] [Related]
13. [Reflux esophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Preliminary report].
Córdova-Villalobos JA; Ramírez-Barba EJ; Ramírez-Covarrubias JC
Rev Gastroenterol Mex; 1996; 61(4):306-9. PubMed ID: 9072780
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Festen HP; Schenk E; Tan G; Snel P; Nelis F
Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
[TBL] [Abstract][Full Text] [Related]
16. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE
Am J Gastroenterol; 1994 Oct; 89(10):1844-8. PubMed ID: 7942680
[TBL] [Abstract][Full Text] [Related]
17. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring.
Ladas SD; Tassios PS; Raptis SA
Am J Gastroenterol; 2000 Feb; 95(2):374-80. PubMed ID: 10685738
[TBL] [Abstract][Full Text] [Related]
18. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
20. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
Dobrilla G; Di Fede F
Clin Ther; 1993; 15 Suppl B():2-13. PubMed ID: 7911400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
